http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102056511-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2840-203 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-87 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-87 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2014-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102056511-B1 |
| titleOfInvention | Therapeutic compositions and methods involving mrna transfection |
| abstract | This disclosure describes compositions and methods that are involved in tumor suppression and inhibition of cellular infection by pathogens. In general, the composition comprises an mRNA cargo that can provide therapeutic benefit after introduction into epithelial cells. In some cases, mRNA may encode a polypeptide. In some cases, the polypeptide may inhibit epithelial cell proliferation. In other embodiments, the polypeptide may be involved in innate immunity. In various embodiments, the polypeptide may comprise catellisin antimicrobial protein (CAMP), calprotectin, S100A8, S100A9, β-defensin, S100A7, secretory leukocyte inhibitor, lipocalin 2, or lysozyme. In some embodiments, the mRNA may comprise a stabilizing moiety such as, for example, a 5 'cap or 3' extension. |
| priorityDate | 2013-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 792.